Orchestra BioMed 2025 Q3 Earnings Revenue Beats Estimates, Net Loss Widens by 35%

Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Wednesday, Nov 12, 2025 12:54 am ET1min read
Aime RobotAime Summary

-

Orchestra BioMed
reported Q3 2025 revenue of $861,000, surpassing estimates by 15.42% despite a 12.8% YoY decline.

- The company narrowed its per-share loss to $0.40 but saw net losses widen by 35% to $20.83 million, with shares rising 7.94% post-earnings.

- Strategic funding of $147.6 million extended cash runway through Q4 2027, supporting clinical trials like the Virtue SAB IDE study and expanded partnerships with Medtronic/Terumo.

- Analysts maintain a "buy" consensus with a $12.00 price target, citing progress in pivotal trials and extended financial runway despite ongoing losses.

Orchestra BioMed (OBIO) reported fiscal 2025 Q3 results on Nov 11, 2025, with revenue exceeding estimates despite a 12.8% year-over-year decline. The company narrowed its per-share loss but saw its net loss expand, while its stock surged post-earnings.

Revenue

Orchestra BioMed’s total revenue fell to $861,000 in Q3 2025, a 12.8% drop from $987,000 in Q3 2024. Partnership revenue accounted for $721,000, while product revenue totaled $140,000. Despite the overall decline, the company outperformed expectations, with revenue surpassing the consensus estimate of $734,800 by 15.42%.

Earnings/Net Income

The company narrowed its per-share loss to $0.40 in Q3 2025, a 2.4% improvement from $0.41 in Q3 2024. However, its net loss widened to $20.83 million, a 35% increase from $15.43 million in the prior year. The sustained losses across four consecutive years highlight ongoing financial challenges.

Post-Earnings Price Action Review

The recent revenue beat and positive market reaction—a 7.94% one-day stock surge—suggest investor optimism. While Q4 2025 revenue is projected at $0.76 million and earnings at -$0.42 per share, the company’s $147.6 million in strategic funding and extended cash runway through Q4 2027 provide a foundation for clinical advancements. Progress in pivotal trials, including the Virtue SAB randomized IDE trial, and a “buy” consensus from analysts with a $12.00 median price target, further support a cautiously optimistic outlook.

Additional News

Orchestra BioMed secured $147.6 million through strategic transactions and equity offerings, extending its cash runway into Q4 2027. The company expanded partnerships with Medtronic and Terumo, including a new right of first refusal (ROFR) agreement with Terumo. Clinical progress includes patient enrollment in the Virtue SAB pivotal trial, targeting mid-2027 completion, and enhancements to the BACKBEAT study protocol. These developments underscore the company’s focus on advancing high-impact biomedical innovations.

Comments



Add a public comment...
No comments

No comments yet